Syncom Formulations (India) Limited (NSE:SYNCOMF)

Market Cap	17.78B
Revenue (ttm)	4.65B
Net Income (ttm)	494.35M
Shares Out	n/a
EPS (ttm)	0.57
PE Ratio	35.96
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	434,177
Average Volume	1,189,251
Open	19.00
Previous Close	18.89
Day's Range	18.75 - 19.00
52-Week Range	13.99 - 27.90
Beta	1.16
RSI	43.09
Earnings Date	Aug 11, 2025

About NSE:SYNCOMF

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations. It provides life care, evolve, and right nutrition products under the Cratus brand. In addition, the company engages in the trading of comm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 998
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SYNCOMF

Financial Performance

In 2024, NSE:SYNCOMF's revenue was 4.65 billion, an increase of 76.55% compared to the previous year's 2.63 billion. Earnings were 494.35 million, an increase of 95.28%.